Status: Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).
Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 12-35Biological sex: AllType: InterventionalSponsor: COUR Pharmaceutical Development Company, Inc.Updated: Jul 2, 2026Locations: 33
Eligibility criteria
Participants who are willing and able to provide Institutional Review Board (IRB... [+14]
Participants unable to comply with prohibited medication outlined in the protoco... [+16]